BioSpace News Archive

Project HOPE is mobilizing critical supplies and other support for frontline health workers in Wuhan, China, who have been battling the new coronavirus outbreak since December 2019.

Establishment Labs Holdings Inc., a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – announced the pricing of its public offering of 2,285,714 common shares at $26.25 per share.

Biocom, the association representing the life science industry of California, today announced that its group purchasing organization (GPO) forged a new alliance with FedEx Corp. (NYSE: FDX) to offer Biocom members exclusive offerings on shipping services.

ImageOne Medical announces the promotion of Tuesday Middaugh Slomovitz, former US Olympian, as COO, beginning January 1, 2020.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once-daily capsule in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome.

Oncology Systems gross orders grew 8% in dollars or 9% in constant currency in the quarter and over the trailing twelve months

IQVIA Holdings Inc., will announce its fourth-quarter and full-year 2019 financial results and issue 2020 guidance before the market opens on Wednesday, February 12, 2020.

Anika Therapeutics, Inc. announced with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share.

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share.